6m7g

Publication Abstract from PubMed

The emergence and spread of antimicrobial resistance highlights the urgent need for new antibiotics. Organoarsenicals have been used as antimicrobials since Paul Ehrlich's salvarsan. Recently a soil bacterium was shown to produce the organoarsenical arsinothricin. We demonstrate that arsinothricin, a non-proteinogenic analog of glutamate that inhibits glutamine synthetase, is an effective broad-spectrum antibiotic against both Gram-positive and Gram-negative bacteria, suggesting that bacteria have evolved the ability to utilize the pervasive environmental toxic metalloid arsenic to produce a potent antimicrobial. With every new antibiotic, resistance inevitably arises. The arsN1 gene, widely distributed in bacterial arsenic resistance (ars) operons, selectively confers resistance to arsinothricin by acetylation of the alpha-amino group. Crystal structures of ArsN1 N-acetyltransferase, with or without arsinothricin, shed light on the mechanism of its substrate selectivity. These findings have the potential for development of a new class of organoarsenical antimicrobials and ArsN1 inhibitors.

Arsinothricin, an arsenic-containing non-proteinogenic amino acid analog of glutamate, is a broad-spectrum antibiotic.,Nadar VS, Chen J, Dheeman DS, Galvan AE, Yoshinaga-Sakurai K, Kandavelu P, Sankaran B, Kuramata M, Ishikawa S, Rosen BP, Yoshinaga M Commun Biol. 2019 Apr 15;2:131. doi: 10.1038/s42003-019-0365-y. eCollection 2019. PMID:30993215^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.